Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics
(NQ:
CLDX
)
37.54
-0.99 (-2.57%)
Streaming Delayed Price
Updated: 3:34 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Celldex Therapeutics
< Previous
1
2
3
Next >
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via
Benzinga
Celldex Therapeutics: Q4 Earnings Insights
February 26, 2024
Via
Benzinga
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
December 20, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
November 10, 2023
Via
Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
February 26, 2024
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks.
Via
Investor's Business Daily
Top Picks 2024: Celldex Therapeutics, Inc.
January 28, 2024
Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to...
Via
Talk Markets
Top 4 Health Care Stocks That May Crash This Month
December 20, 2023
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
November 17, 2023
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.
Via
InvestorPlace
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered
November 08, 2023
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share.
Via
Benzinga
Why Celldex Therapeutics Blasted 13% Higher on Monday
November 06, 2023
The biotech's CSU treatment advanced in the laboratory.
Via
The Motley Fool
4 Analysts Have This to Say About Celldex Therapeutics
May 31, 2023
Via
Benzinga
Celldex Therapeutics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Why Celldex Therapeutics Shares Are Trading Higher Today
February 27, 2023
Via
Benzinga
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
November 06, 2023
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
Via
Investor's Business Daily
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...
Via
Benzinga
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
November 06, 2023
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to...
Via
Benzinga
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
December 19, 2022
Via
Benzinga
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
July 05, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 06, 2023
Via
Benzinga
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27
August 27, 2023
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
August 22, 2023
Via
Benzinga
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
May 11, 2023
Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2023
Via
Benzinga
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
February 27, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today?
February 01, 2023
The Federal Reserve's interest rate hike announcements have the potential to cause significant volatility in the stock market.
Via
Benzinga
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 14, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Topics
Death
Exposures
Death
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 13, 2022
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX<
Via
Benzinga
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
August 31, 2022
Celldex Therapeutics (NASDAQ:CLDX) brought in sales totaling $163 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 56.2%, resulting in a loss of $36.00...
Via
Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
July 05, 2022
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.